Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system

Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA‐approved drug rapamycin has been shown to promote lifespan and delay age‐related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucos...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Aging Cell
Egile Nagusiak: Arriola Apelo, Sebastian I., Neuman, Joshua C., Baar, Emma L., Syed, Faizan A., Cummings, Nicole E., Brar, Harpreet K., Pumper, Cassidy P., Kimple, Michelle E., Lamming, Dudley W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2015
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4717280/
https://ncbi.nlm.nih.gov/pubmed/26463117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/acel.12405
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak